Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate and: Gleason > 8 OR prostatic
             specific antigen (PSA) > 20 and more than 1 positive core

          -  Patients with Eastern Cooperative Oncology Group performance scale (ECOG PS) 0 or 1

          -  Clinical stage T3 or less as demonstrated by abdominal/pelvic computed tomography (CT)
             or magnetic resonance imaging (MRI) will be selected as the prostate is resectable

          -  Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3
             months prior to randomization

          -  Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors
             within 3 months prior to randomization

          -  Serum albumin >= 3.0 g/dL

          -  Glomerular filtration rate (GFR) >= 45 mL/min

          -  Serum potassium >= 3.5 mmol/L

          -  Serum total bilirubin =< 1.5 × upper limit of normal (ULN) (Note: In subjects with
             Gilbert's syndrome, if total bilirubin is > 1.5 × ULN, measure direct and indirect
             bilirubin and if direct bilirubin is =< 1.5 × ULN, subject may be eligible)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × ULN

          -  Medications known to lower the seizure threshold must be discontinued or substituted
             at least 4 weeks prior to study entry

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

        Exclusion Criteria:

          -  Clinical stage T4 (invasion into rectum or ureters) significantly increases the
             morbidity of the surgery

               -  Patients with rectal or ureteral invasion will be considered to have unresectable
                  disease

          -  History of any of the following:

               -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke
                  within 1year to randomization, brain arteriovenous malformation, Schwannoma,
                  meningioma, or other benign central nervous system [CNS] or meningeal disease
                  which may require treatment with surgery or radiation therapy)

               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
                  failure, arterial within 6 months prior to randomization

               -  Venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident
                  including transient ischemic attacks) within 6 months prior to randomization

               -  Clinically significant ventricular arrhythmias within 6 months prior to
                  randomization

          -  Metastatic prostate cancer

          -  Baseline moderate or severe hepatic impairment (Child-Pugh class B or C)